All Updates

All Updates

icon
Filter
Partnerships
Intellia Therapeutics and ReCode partner to develop gene therapies for cystic fibrosis
Human Gene Editing
Feb 15, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Product updates
Uber releases five new features for holiday travel season
Travel Tech
Yesterday
Human Gene Editing

Human Gene Editing

Feb 15, 2024

Intellia Therapeutics and ReCode partner to develop gene therapies for cystic fibrosis

Partnerships

  • Massachusetts-based gene-editing biotech company Intellia Therapeutics and Texas-based genetic medicines company ReCode Therapeutics have entered an agreement to develop gene-editing treatments for cystic fibrosis (CF).

  • As part of the agreement, Intellia will receive pre-specified development and commercial milestone payments as well as royalties from sales. Intellia will also have an option to lead the commercialization in the US for specific programs.

  • The partnership will integrate Intellia’s CRISPR-based gene editing platform and ReCode’s lipid nanoparticle delivery system to accurately modify CF-causing gene mutations. Intellia will oversee the design of the editing strategy while ReCode will handle clinical development and commercialization. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.